CLINICAL TRIAL SUMMARY

MDACC Study No:2012-1155 (clinicaltrials.gov NCT No: NCT01287741)
Title:PHASE III, MULTICENTER, OPEN-LABEL, RANDOMIZED TRIAL COMPARING THE EFFICACY OF GA101 (RO5072759) IN COMBINATION WITH CHOP (G-CHOP) VERSUS RITUXIMAB AND CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS WITH CD20-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Principal Investigator:Luis E. Fayad
Treatment Agent:Cyclophosphamide; Doxorubicin; GA101; Prednisolone; Prednisone; Rituximab; Vincristine
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if GA101 in combination
with chemotherapy ("CHOP" chemotherapy with cyclophosphamide, doxorubicin,
vincristine, and prednisone or prednisolone) can help to control the disease
for longer than standard treatment (rituximab plus CHOP chemotherapy). The
safety of these treatments will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase III
Treatment Agents:Cyclophosphamide
Doxorubicin
GA101
Prednisolone
Prednisone
Rituximab
Vincristine
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Genentech, Inc
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Luis E. Fayad
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:1-877-MDA-6789


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults